Cytokinetics (CYTK) EVP Callos sells stock to cover RSU taxes

Rhea-AI Filing Summary

CYTOKINETICS INC executive Andrew Callos reported a small, tax-related stock sale. On the vesting of restricted stock units, he sold 2,582 shares of common stock on March 9, 2026 at $60.72 per share to satisfy company tax withholding obligations, and now directly holds 47,858 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		2,582	D	$60.72	47,858	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell to cover transaction to satisfy company tax withholding obligations upon vesting of RSUs.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cytokinetics (CYTK) executive Andrew Callos report in this Form 4?

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, reported a small sale of company stock. The transaction relates to restricted stock units vesting and was used to cover tax withholding obligations, rather than reflecting a large discretionary change in his ownership position.

How many Cytokinetics (CYTK) shares did Andrew Callos sell and at what price?

Andrew Callos sold 2,582 shares of Cytokinetics common stock at $60.72 per share. This open-market sale was tied to the vesting of restricted stock units and was undertaken to satisfy company tax withholding requirements associated with that equity compensation event.

Why did Andrew Callos sell Cytokinetics (CYTK) shares according to the filing footnote?

The filing footnote states the sale was a “sell to cover” transaction. It was executed specifically to satisfy company tax withholding obligations triggered when Andrew Callos’s restricted stock units vested, making it a tax-related event rather than a purely discretionary portfolio decision.

How many Cytokinetics (CYTK) shares does Andrew Callos hold after the reported sale?

After selling 2,582 shares, Andrew Callos directly owns 47,858 shares of Cytokinetics common stock. This remaining stake shows that the reported sale represents only a small portion of his total holdings, consistent with a routine tax-related transaction tied to RSU vesting.

What role does Andrew Callos hold at Cytokinetics (CYTK)?

Andrew Callos serves as Executive Vice President and Chief Commercial Officer at Cytokinetics. His position means he is a senior officer subject to insider reporting rules, so transactions in Cytokinetics stock must be disclosed on Form 4, as reflected in this filing.